ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 812

Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide

Aleksey Mitev1, Daria Feldmann1, Moritz Binder2, Kim Möller3, Anna-Maria Kanne1, Thomas Hügle4, Peter M. Villiger5, Reinhard Voll6, Stephanie Finzel1 and Florian Kollert7, 1Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 2Department of Internal Medicine, Mayo Clinic, Rochester, MN, 3Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 4Rheumatology, University Hospital Lausanne (CHUV), Lausanne, Switzerland, 5Rheumatology and Clin Immunol, Bern, Switzerland, 6Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 7Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: C Reactive Protein, Cardiovascular disease, cyclophosphamide, inflammation and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Sclerosis and Related Disorders – Clinical Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Elevated levels of C-reactive protein (CRP) in systemic sclerosis (SSc) have been linked to early inflammatory stages of the disease. This study has been set to investigate CRP levels in a longitudinal cohort of SSc patients and to correlate these findings with comorbidities and disease characteristics.

Methods: In this retrospective study patients with SSc were recruited from the outpatient clinic of the Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg. Only patients with at least three consecutive visits over at least one year were included in this study. CRP serum levels were measured at every visit and categorized as positive if CRP concentrations were ≥ 5mg/l. Subjects with elevated CRP levels at more than 80% of visits were defined as inflammatory SSc. The longitudinal CRP profile was correlated to comorbidities and disease characteristics.

Results: A total of 1,815 consecutive visits of 131 SSc patients were analyzed. Over the observed time span (91 [136-56] months) 18.3% (n=24) of patients had continuously elevated CRP levels (inflammatory SSc), whereas in 29% (n=38) CRP levels were always in the normal range. There was no association between disease duration and CRP levels at first visit (p>0.5). Inflammatory SSc was associated (p<0.05) with anti-topoisomerase I-antibodies, diffuse cutaneous SSc (dcSSC), pulmonary fibrosis, rheumatoid arthritis, and cardiac arrhythmia (p<0.05). Moreover, patients with inflammatory SSc revealed higher modified Rodnan skin scores (mRSS), and lower FCV, TLC, and DLCO (p<0.001). Even treatment with cyclophosphamide (CYC) did not alter CRP levels (n=12, median dose 4.5 g (3-10), median CRP before CYC 18.0 mg/l, after CYC 17.7 mg/l, p=0.754).

Conclusion: Inflammatory SSc is characterized by a more severe disease phenotype and high morbidity. Even treatment with CYC does not alter CRP levels in these patients.


Disclosure: A. Mitev, None; D. Feldmann, None; M. Binder, None; K. Möller, None; A. M. Kanne, None; T. Hügle, None; P. M. Villiger, None; R. Voll, None; S. Finzel, None; F. Kollert, None.

To cite this abstract in AMA style:

Mitev A, Feldmann D, Binder M, Möller K, Kanne AM, Hügle T, Villiger PM, Voll R, Finzel S, Kollert F. Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/inflammatory-stays-inflammatory-a-subgroup-of-systemic-sclerosis-characterized-by-high-morbidity-and-inflammatory-resistance-to-cyclophosphamide/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-stays-inflammatory-a-subgroup-of-systemic-sclerosis-characterized-by-high-morbidity-and-inflammatory-resistance-to-cyclophosphamide/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology